Anti-CXCL12 / SDF-1 beta antibody

Cat.#: 101052

Special Price 145.0 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-CXCL12 / SDF-1 beta antibody
  • Documents
  • Description
    Rabbit polyclonal to CXCL12 / SDF-1 beta
  • Tested applications
    IHC-P
  • Species reactivity
    Human CXCL12 / SDF-1 beta
  • Alternative names
    AI174028 antibody; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) antibody; Cxcl12 antibody; CXCL12 antibody; PBSF antibody; Pbsf antibody; Scyb12 antibody; SCYB12 antibody; Sdf1 antibody; SDF1 antibody; Sdf1a antibody; SDF1A antibody; SDF-1a antibody; Sdf1b antibody; SDF1B antibody; SDF-1b antibody; Tlsf antibody; Tlsfa antibody; TLSF-a antibody; Tlsfb antibody; TLSF-b antibody; Tpar1 antibody; TPAR1 antibody; IRH antibody; PBSF antibody; SDF1 antibody; TLSF antibody; TPAR1 antibody; SCYB12 antibody; Pbsf antibody; Sdf1 antibody; Tlsf antibody; Tpar1 antibody; Scyb12 antibody
  • Immunogen
  • Isotype
    Rabbit IgG
  • Preparation
    Produced in rabbits immunized with purified, recombinant Human CXCL12 / SDF-1 beta (rh CXCL12 / SDF-1 beta; P48061-1; Lys22-Met93). CXCL12 / SDF-1 beta specific IgG was purified by Human CXCL12 / SDF-1 beta affinity chromatography.
  • Clonality
    Polyclonal
  • Formulation
    0.2 μm filtered solution in PBS
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    IHC-P: 0.1-2 μg/ml

  • Validations

    CXCL12 / SDF-1 beta Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    CXCL12 / SDF-1 beta Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    CXCL12 / SDF-1 beta Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    CXCL12 / SDF-1 beta Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    CXCL12 / SDF-1 beta Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    CXCL12 / SDF-1 beta Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

  • Background
    The human stromal cell-derived factor-1 (SDF1), also known as CXCL12, is a small (8 kDa) cytokine highly conserved chemotactic cytokine belonging to the large family of CXC chemokines. SDF1 is expressed in two isoforms from a single gene that encodes two splice variants, SDF1α and SDF1β, which are identical except for the four residues present in the C-terminus of SDF1β but absent from SDF1α. The chemokine CXCL12 [stromal cell-derived factor-1 (SDF-1)] binds primarily to CXC receptor 4 (CXCR4; CD184). The binding of CXCL12 to CXCR4 induces intracellular signaling through several divergent pathways initiating signals related to chemotaxis, cell survival and/or proliferation, increase in intracellular calcium, and gene transcription. CXCL12 and CXCR4 that have been widely characterized in peripheral tissues and delineate their main functions in the CNS. Extensive evidence supports CXCL12 as a key regulator for early development of the CNS. In the mature CNS, CXCL12 modulates neurotransmission, neurotoxicity and neuroglial interactions. CXCL12 has crucial roles in the formation of multiple organ systems during embryogenesis and in the regulation of bone marrow haematopoiesis and immune function in the postnatal organism. Although considered an important factor in normal bone metabolism, recent studies implicate CXCL12 in the pathogenesis of several diseases involving the skeleton, including rheumatoid arthritis and cancers that metastasize to bone. The CXCL12/CXCR4 axis is involved in tumor progression, angiogenesis, metastasis, and survival. Pathologically enhanced CXCL12 signaling may promote the formation of new vessels through recruiting circulating endothelial progenitor cells or directly enhancing the migration/growth of endothelial cells. Therefore, CXCL12 signaling represents an important mechanism that regulates brain tumor angiogenesis/vasculogenesis and may provide potential targets for anti-angiogenic therapy in malignant gliomas.
  • References
    • Bleul, C.C. et al., 1996, Nature. 382: 829-833.
    • Sapede, D. et al., 2005, Proc. Natl. Acad. Sci. USA. 102: 1714-1718.
    • Delgado, M.B. et al., 2001, Eur. J. Immunol. 31: 699-707.
    • Orimo, A. et al., 2005, Cell. 121: 335-348.
    • Kryczek, I. et al., 2007, Am. J. Physiol. Cell. Physiol. 292: C987-995.
    • Bbalabanian, K. et al., 2005, J. Biol. Chem. 280: 35760-35766.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"